ZA200905334B - Process for obtaining the crystalline form V of agomelatine - Google Patents

Process for obtaining the crystalline form V of agomelatine Download PDF

Info

Publication number
ZA200905334B
ZA200905334B ZA200905334A ZA200905334A ZA200905334B ZA 200905334 B ZA200905334 B ZA 200905334B ZA 200905334 A ZA200905334 A ZA 200905334A ZA 200905334 A ZA200905334 A ZA 200905334A ZA 200905334 B ZA200905334 B ZA 200905334B
Authority
ZA
South Africa
Prior art keywords
crystalline form
agomelatine
formula
compound
preparation
Prior art date
Application number
ZA200905334A
Other languages
English (en)
Inventor
Damien Martins
Gerard Coquerel
Julie Linol
Pascal Langlois
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40418877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200905334(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of ZA200905334B publication Critical patent/ZA200905334B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)
ZA200905334A 2008-08-05 2009-07-30 Process for obtaining the crystalline form V of agomelatine ZA200905334B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0804466A FR2934856B1 (fr) 2008-08-05 2008-08-05 Nouveau procede d'obtention de la forme cristalline v de l'agomelatine

Publications (1)

Publication Number Publication Date
ZA200905334B true ZA200905334B (en) 2010-05-26

Family

ID=40418877

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200905334A ZA200905334B (en) 2008-08-05 2009-07-30 Process for obtaining the crystalline form V of agomelatine

Country Status (45)

Country Link
US (1) US8252957B2 (sr)
EP (1) EP2151430B1 (sr)
JP (1) JP5047240B2 (sr)
KR (1) KR101118335B1 (sr)
CN (1) CN101643432B (sr)
AP (1) AP3196A (sr)
AR (1) AR074889A1 (sr)
AT (1) ATE518825T1 (sr)
AU (1) AU2009203071B2 (sr)
BR (1) BRPI0903058A2 (sr)
CA (1) CA2674770C (sr)
CL (1) CL2009001685A1 (sr)
CO (1) CO6120151A1 (sr)
CR (1) CR10952A (sr)
CY (1) CY1111873T1 (sr)
DK (1) DK2151430T3 (sr)
EA (1) EA016896B1 (sr)
EC (1) ECSP099554A (sr)
ES (1) ES2371047T3 (sr)
FR (1) FR2934856B1 (sr)
GE (1) GEP20125408B (sr)
GT (1) GT200900215A (sr)
HN (1) HN2009001437A (sr)
HR (1) HRP20110712T1 (sr)
IL (1) IL200126A (sr)
JO (1) JO2812B1 (sr)
MA (1) MA31223B1 (sr)
ME (1) ME00929B (sr)
MX (1) MX2009008046A (sr)
MY (1) MY151042A (sr)
NI (1) NI200900154A (sr)
NZ (1) NZ578826A (sr)
PE (1) PE20100153A1 (sr)
PL (1) PL2151430T3 (sr)
PT (1) PT2151430E (sr)
RS (1) RS52002B (sr)
SA (1) SA109300499B1 (sr)
SG (1) SG158830A1 (sr)
SI (1) SI2151430T1 (sr)
SV (1) SV2009003345A (sr)
TW (1) TW201008901A (sr)
UA (1) UA102816C2 (sr)
UY (1) UY32014A (sr)
WO (1) WO2010015747A1 (sr)
ZA (1) ZA200905334B (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101781226B (zh) 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
EP2705023A4 (en) * 2011-01-04 2014-11-19 Symed Labs Ltd PROCESSES FOR THE PREPARATION OF N- [2- (7-METHOXY-1-NAPHTHYLLELYHYL) ACETAMIDE
WO2012130837A1 (en) 2011-03-28 2012-10-04 Ratiopharm Gmbh Solid agomelatine in non-crystalline form
CA2877410A1 (en) 2012-07-16 2014-01-23 Ratiopharm Gmbh Complex of agomelatine and cyclodextrin
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1703641A1 (ru) * 1988-02-23 1992-01-07 Ростовский государственный университет Способ получени 3,5-ди-трет.бутил-4-оксиацетанилида
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2889522B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889521B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
US20080280991A1 (en) * 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted naphthalenes
FR2923482B1 (fr) * 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
RS52002B (sr) 2012-04-30
JO2812B1 (en) 2014-09-15
IL200126A (en) 2013-04-30
ES2371047T3 (es) 2011-12-26
AR074889A1 (es) 2011-02-23
KR20100017070A (ko) 2010-02-16
HK1141005A1 (en) 2010-10-29
UY32014A (es) 2010-01-29
PE20100153A1 (es) 2010-03-06
KR101118335B1 (ko) 2012-03-09
EA016896B1 (ru) 2012-08-30
PL2151430T3 (pl) 2011-12-30
PT2151430E (pt) 2011-08-25
ME00929B (me) 2012-06-20
EA200900944A1 (ru) 2010-04-30
CN101643432A (zh) 2010-02-10
SA109300499B1 (ar) 2013-10-06
GT200900215A (es) 2011-07-19
MA31223B1 (fr) 2010-03-01
CO6120151A1 (es) 2010-01-29
CN101643432B (zh) 2012-12-12
CL2009001685A1 (es) 2010-07-19
US8252957B2 (en) 2012-08-28
NI200900154A (es) 2010-03-25
UA102816C2 (ru) 2013-08-27
CA2674770C (fr) 2012-04-17
WO2010015747A1 (fr) 2010-02-11
SI2151430T1 (sl) 2011-10-28
SG158830A1 (en) 2010-02-26
ECSP099554A (es) 2010-03-31
HRP20110712T1 (hr) 2011-11-30
FR2934856B1 (fr) 2010-08-13
TW201008901A (en) 2010-03-01
US20100036165A1 (en) 2010-02-11
HN2009001437A (es) 2011-09-22
JP5047240B2 (ja) 2012-10-10
EP2151430A1 (fr) 2010-02-10
DK2151430T3 (da) 2011-11-21
AP2009004936A0 (en) 2009-08-31
SV2009003345A (es) 2010-02-01
CY1111873T1 (el) 2015-11-04
AU2009203071B2 (en) 2013-10-31
GEP20125408B (en) 2012-02-27
JP2010037345A (ja) 2010-02-18
NZ578826A (en) 2010-11-26
CR10952A (es) 2009-10-15
EP2151430B1 (fr) 2011-08-03
MY151042A (en) 2014-03-31
AP3196A (en) 2015-03-31
AU2009203071A1 (en) 2010-02-25
MX2009008046A (es) 2010-03-23
FR2934856A1 (fr) 2010-02-12
CA2674770A1 (fr) 2010-02-05
BRPI0903058A2 (pt) 2010-05-25
IL200126A0 (en) 2010-05-31
ATE518825T1 (de) 2011-08-15

Similar Documents

Publication Publication Date Title
ME00928B (me) Novi postupak za sintezu agomelatina
AU2009203071B2 (en) New process for obtaining the crystalline form V of agomelatine
SG186548A1 (en) New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
Veverka et al. Cocrystals of quercetin: synthesis, characterization, and screening of biological activity
RS55316B1 (sr) Novi oblik kristalnog vi agomelatina, postupak pripreme i njegove farmaceutske kompozicije
ZA200905333B (en) Process for the synthesis of agomelatine
ZA200606453B (en) Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it
Pandit et al. Structure–activity-relationship studies of conformationally restricted analogs of combretastatin A-4 derived from SU5416
NO337010B1 (no) Ny krystallinsk form III av agomelatin, fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inneholdende den
NZ578381A (en) New process for the synthesis of agomelatine or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
RS55918B1 (sr) Mešani kristal agomelatina (oblik-viii), postupak dobijanja i njegova upotreba i farmaceutske kompozicije koje ga sadrže
Zhang et al. Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors
HK1141005B (en) New process for obtaining the crystalline form v of agomelatine
Tekluu et al. Synthesis and Biological Evaluation of 1H-(Indole-5-yl)-3-Substituted-1, 2, 4-Oxadiazoles as Novel 5-Lox Inhibitors
CN106336363B (zh) 一种沙芬酰胺甲磺酸盐晶型c及其制备方法
JPWO2005105731A1 (ja) 新規な結晶性パントテン酸カルシウム
JP3698640B6 (ja) ２−（２′−ヒドロキシ−３′，５′−ジ−ｔ−アミルフェニル）ベンゾトリアゾールＩＩ型結晶変態、その製法、それを含む組成物およびそれらを用いた紫外線吸収剤
JP3698641B2 (ja) ２−（２′−ヒドロキシ−３′，５′−ジ−ｔ−アミルフェニル）ベンゾトリアゾールＩＩＩ型結晶変態、その製法、それを含む組成物
CN102503955A (zh) 邻苯二甲酰亚胺并氮杂酰胺杂15-冠醚及其合成方法
CN105473551A (zh) 阿戈美拉汀和对甲苯磺酸的共晶的新形式、其制备方法和包含其的药物组合物
EP1646607A2 (en) A method for the preparation of crystalline dexloxiglumide